Series B · Biotech
Ambrosia Biosciences secures $100m Series B commitments
Ambrosia’s oversubscribed Series B supports its oral GLP-1 programme through clinical-trial initiation.
Committed capital for a clinical transition
Ambrosia Biosciences announced an oversubscribed $100m Series B on March 31, 2026, describing the financing as committed capital. Blue Owl Healthcare Opportunities, Redmile and Deep Track Capital co-led the round.
Existing investors BVF Partners and Boulder Ventures joined new investors Janus Henderson Investors, Samsara BioCapital and an undisclosed institution. The company intends the financing to fund initiation of a Phase 1 trial for its oral GLP-1 candidate and continued development of other cardiometabolic programmes, including GIP and amylin.
Funding history
Series B · This round$100M